Want to create an interactive transcript for this episode?
Podcast: What the Flux
Episode: ResMed investors sleep soundly | Figma pops 250% on IPO | Ozempic faces a new challenger
Description: ResMed beats full‑year earnings and revenue forecasts thanks to a growth in snorers around the world. Figma, the design software, has tripled its market value on its IPO debut in one of the biggest first day pops for a US software company ever. Novo Nordisk, the company behind Ozempic, has seen market value slashed by over €60 billion after investors worry it’s losing the obesity drug race. _ Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay  Daily...